Autologous Hematopoietic Stem Cell Transplantation Combined With CAR-T Cells in the Treatment of Refractory and Relapsed Malignant Lymphoma

Inclusion Criteria:

• 1.Male or female, 18-75 years old (including the threshold value); 2. According to the 2016 WHO classification criteria for lymphocytic tumors, histologically confirmedinclude: DLBCL (NOS); follicular lymphoma, chronic lymphocytic leukemia/smalllymphocytic lymphoma transformed DLBCL, and PMBCL and high-grade B-cell lymphomaSubject. 3.R/R B-NHL (conform one of the following conditions)

1. The subject did not remission or relapsed after receiving second-line orhigher-line chemotherapy
2. Primary resistance
3. The subject relapsed after receiving autologous hematopoietic stem celltransplantation

Exclusion Criteria:

• Subjects with any of the following exclusion criteria were not eligible for thistrial:

1. History of craniocerebral trauma, conscious disturbance, epilepsy,cerebrovascular ischemia, and cerebrovascular, hemorrhagic diseases;
2. Electrocardiogram shows prolonged QT interval, severe heart diseases such assevere arrhythmia in the past;
3. Pregnant (or lactating) women;
4. Patients with severe active infections (excluding simple urinary tract infectionand bacterial pharyngitis);
5. Active infection of hepatitis B virus or hepatitis C virus;
6. Those who have used any gene therapy products before.
7. The proiferation rate is less than 5 times response to CD3/CD28 co-stimulationsignal;
8. Serum creatinine > 2.5mg/dl or ALT / AST > 3 times ULN or bilirubin > 2.0mg/dl;
9. Those who suffer from other uncontrolled diseases are not suitable to join thestudy;
10. HIV infection;
11. Any situation that the researchers believe may increase the risk of patients orinterfere with the test results.